Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Pharmacy Administration, Policy and Regulation (103)
- Social and Behavioral Sciences (71)
- Economics (57)
- Health Economics (53)
- Public Affairs, Public Policy and Public Administration (50)
-
- Economic Policy (44)
- Public Health (37)
- Life Sciences (29)
- Pharmacology, Toxicology and Environmental Health (25)
- Medical Pharmacology (24)
- Medical Sciences (24)
- Other Pharmacology, Toxicology and Environmental Health (24)
- Other Pharmacy and Pharmaceutical Sciences (23)
- Pharmaceutics and Drug Design (20)
- Business (19)
- Medical Specialties (17)
- Law (16)
- Health Services Research (15)
- Chemicals and Drugs (14)
- Health and Medical Administration (12)
- Diseases (10)
- Community Health and Preventive Medicine (9)
- Pharmaceutical Preparations (8)
- Epidemiology (7)
- Health Law and Policy (7)
- Bioethics and Medical Ethics (6)
- Business Administration, Management, and Operations (6)
- Institution
-
- Universitas Indonesia (47)
- Universitas Padjadjaran (23)
- Chapman University (21)
- Bentley University (14)
- Virginia Commonwealth University (13)
-
- West Virginia University (10)
- Bulletin of the Faculty of Pharmacy Cairo University (8)
- Marshall University (7)
- Ohio Northern University (6)
- University of Kentucky (5)
- Chulalongkorn University (4)
- City University of New York (CUNY) (3)
- Duquesne University (3)
- Population Council (3)
- Seton Hall University (3)
- University of New Mexico (3)
- University of Tennessee Health Science Center (3)
- Baptist Health South Florida (2)
- Children's Mercy Kansas City (2)
- MaineHealth (2)
- Notre Dame Law School (2)
- Rowan University (2)
- University of Nevada, Las Vegas (2)
- University of New Hampshire (2)
- Ursinus College (2)
- Alayen Iraqi University (1)
- Augustana College (1)
- Bemidji State University (1)
- Bowling Green State University (1)
- Bucknell University (1)
- Keyword
-
- FDA (8)
- Pharmacology and Clinical Pharmacy (8)
- Cost (7)
- Economic burden (6)
- Innovation (6)
-
- Cancer (5)
- Drug development (5)
- Medicare (5)
- Pharmaceutical (5)
- Pharmaceutical innovation (5)
- Pharmaceuticals (5)
- Social value (5)
- COVID-19 (4)
- Cost-effectiveness (4)
- Insurance (4)
- Machine Learning (4)
- Medicaid (4)
- Older adults (4)
- Pharmaceutical industry (4)
- Pharmacoeconomics (4)
- Product affordability (4)
- United States (4)
- Biotechnology (3)
- Clinical trials (3)
- Cost effectiveness analysis (3)
- Cost variation (3)
- Drug pricing (3)
- Drugs (3)
- Economic evaluation (3)
- FDA-approved products (3)
- Publication Year
- Publication
-
- Jurnal Ekonomi Kesehatan Indonesia (47)
- Pharmacology and Clinical Pharmacy Research (23)
- Theses and Dissertations (14)
- Graduate Theses, Dissertations, and Problem Reports (ETD) (9)
- Bulletin of Faculty of Pharmacy Cairo University (8)
-
- Natural & Applied Sciences Faculty Publications (7)
- Pharmacy Faculty Articles and Research (7)
- CISI Publication (6)
- Pharmaceutical Sciences (PhD) Dissertations (6)
- Pharmacy and Wellness Review (5)
- Electronic Theses and Dissertations (4)
- Pharmaceutical Sciences (MS) Theses (4)
- The Thai Journal of Pharmaceutical Sciences (4)
- Theses and Dissertations--Pharmacy (4)
- Law Faculty Scholarship (3)
- Seton Hall University Dissertations and Theses (ETDs) (3)
- Theses and Dissertations (ETD) (3)
- All Publications (2)
- Faculty Scholarship (2)
- Honors Theses (2)
- MaineHealth Maine Medical Center (2)
- Management Faculty Research (2)
- Notre Dame Journal on Emerging Technologies (2)
- Pharmaceutical Sciences ETDs (2)
- Pharmacy Practice & Administration (2)
- Reproductive Health (2)
- Theses, Dissertations and Capstones (2)
- A with Honors Projects (1)
- AUIQ Complementary Biological System (1)
- Accounting Faculty Research (1)
- Publication Type
Articles 121 - 150 of 230
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Evaluasi Implementasi Jaminan Persalinan (Jampersal) Di Indonesia, Mazda Novi Mukhlisa, Rosa Estetika
Evaluasi Implementasi Jaminan Persalinan (Jampersal) Di Indonesia, Mazda Novi Mukhlisa, Rosa Estetika
Jurnal Ekonomi Kesehatan Indonesia
Jampersal as a transfer fund from central to district government is provided to support maternal and child health services aiming to increase access to health services for pregnant women, childbirth and postpartum mothers, also newborns to competent health facilities. This analysis aimed to evaluate the use of Jampersal in increasing institutional delivery using quantitative and qualitative approaches. For the quantitative approach, this analysis used Riskesdas 2018 and routine data from the Ministry of Health. The data was analyzed using benefit incidence analysis (BIA) and linear regression. The quantitative approach was conducted at two levels, the individual level (80,459 pregnant women) …
Determinan Sosial Ekonomi Terhadap Berat Badan Lebih Dan Obesitas Di Indonesia: Analisis Data Ifls 2014, Fajar Nugraha, Riki Relaksana, Adiatma Y. M. Siregar
Determinan Sosial Ekonomi Terhadap Berat Badan Lebih Dan Obesitas Di Indonesia: Analisis Data Ifls 2014, Fajar Nugraha, Riki Relaksana, Adiatma Y. M. Siregar
Jurnal Ekonomi Kesehatan Indonesia
The phenomenon of overweight and obesity has become a serious problem in various countries, especially in Indonesia. According to WHO in 2016 there were 2.8 million people who died due to the problem of overweight and obesity, while according to the Indonesian Ministry of Health the prevalence of overweight and obesity in Indonesia in 2018 reached 13,6% and 21.8%. One of the factors that cause overweight and obesity is socio-economic status. However, there are often differences regarding the effect of socioeconomic status on obesity in developing and developed countries. This study aims to identify the determinant factors of socioeconomic status …
Strategi Implementasi Jaminan Kesehatan Nasional Dengan Metode Balanced Scoredcard: Studi Kasus Di Rumah Sakit X Tangerang Tahun 2018, Luh Putu Sinthya Ulandari, Jaslis Ilyas, Putu Ayu Indrayathi
Strategi Implementasi Jaminan Kesehatan Nasional Dengan Metode Balanced Scoredcard: Studi Kasus Di Rumah Sakit X Tangerang Tahun 2018, Luh Putu Sinthya Ulandari, Jaslis Ilyas, Putu Ayu Indrayathi
Jurnal Ekonomi Kesehatan Indonesia
One of the private hospital successful implementation the National Health Insurance with cost efficiency without neglecting the quality of service is X Hospital. This study aimed to finding out the strategy of X Hospital in the implementation of the National Health Insurance with Balanced Scorecard. The research was conducted in May 2018 using qualitative approach. Data was collected through in-depth interview to 7 informants from hospital and 2 informants from BPJS Kesehatan. The subjects were selected purposively and the data was analyzed using thematic analysis. The results show that there are several strategies that have been developed and implemented, including: …
Hubungan Realisasi Alokasi Dana Kesehatan Dan Pemanfaatan Pelayanan Kesehatan Ibu Di Indonesia, Izzun Nafiah
Hubungan Realisasi Alokasi Dana Kesehatan Dan Pemanfaatan Pelayanan Kesehatan Ibu Di Indonesia, Izzun Nafiah
Jurnal Ekonomi Kesehatan Indonesia
Increasing the utilization of maternal health services is an important target for the Indonesian government to increase the achievement of the SDGs targets. Funds budgeted for the health sector are at least 5% of the APBN and 10% of APBD excluding salaries. This is smaller than countries in the low-income category, while WHO shows that an increase in the allocation of health funds has a positive relationship with the degree of public health. Therefore, this study aims to determine whether there is a relationship between the realization of health fund allocation and the utilization of maternal health services in Indonesia. …
Analisis Faktor Socioeconomic Status (Ses) Terhadap Kesehatan Mental: Gejala Depresi Di Indonesia, Yustika Dewi, Riki Relaksana, Adiatma Y. M. Siregar
Analisis Faktor Socioeconomic Status (Ses) Terhadap Kesehatan Mental: Gejala Depresi Di Indonesia, Yustika Dewi, Riki Relaksana, Adiatma Y. M. Siregar
Jurnal Ekonomi Kesehatan Indonesia
According to the World Federation of Mental Health, 1 of 5 people in the world experiences a mental disorder. Several studies have mentioned that one of the primary factors that cause mental disorders is the low of socioeconomic status in developing countries. Therefore, this study was conducted to determine the influence of socioeconomic status factors on depressive symptoms as a mental disorder, in one of the developing countries, Indonesia. This study uses a quantitative method based on secondary data taken from the Indonesia Family Life Survey (IFLS) wave 5 using the CESD-R 10 questionnaire for depressive symptom variables. Depression symptom …
Why Some People Consume Counterfeit Drugs In Benin, Maxime A. Ahouansou
Why Some People Consume Counterfeit Drugs In Benin, Maxime A. Ahouansou
International Programs
Despite the threat counterfeit drugs represent to health and the government’s endeavor to discourage their consumption, some people in Benin still prefer buying medicine in the underground economy. This research purported to understand the causes of the phenomenon. The research method used a survey of a sample of sixty-eight people randomly selected at Cotonou, a city with a population representative of Benin general population status regarding socio-economic conditions. The data about people's habits regarding drug consumption, monthly income, insurance coverage, and reasons why people chose to buy counterfeit medicines were collected and analyzed using Excel Spreadsheet. The analysis of those …
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies In Cystic Fibrosis: A Retrospective Evaluation Of A Nationwide Specialty Pharmacy Database, Zumi Mehta
Electronic Theses and Dissertations
Background: Cystic fibrosis (CF) is a progressive, genetic disorder caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with CF experience excessive mucus build up and infections leading to complications in the pancreas, lungs, and other organs. There has been a paradigm shift in the treatment of CF with the introduction of CFTR modulator therapies and given their high acquisition cost, assessing their economic burden along with the adherence rate of patients is imperative. Objective: (i) To assess the utilization of CFTR modulator therapies in a specialty pharmacy CF patient population and (ii) to calculate …
Demographics Of Opioid Prescriptions, Isaac Linton, Simon Condliffe
Demographics Of Opioid Prescriptions, Isaac Linton, Simon Condliffe
Economics & Finance Student Work
The author ran Linear Probability Model and Logistic Model regressions on data from the 2017 Medical Expenditures Panel Survey to determine demographics of opioid prescriptions. The dependent variable was opioid prescription received (Y/N) and independent variables included age, education level, relative income, race, insurance status, etc. Results of the regressions showed that people with public or private insurance are more likely to be prescribed an opioid, that the problem mainly affects white people, and that as educational attainment increases, likelihood of opioid prescription decreases.
Profitability Of Large Pharmaceutical Companies Compared With Other Large Public Companies, Fred D. Ledley, Sarah Shonka Mccoy, Gregory Vaughan, Ekaterina Galkina Cleary
Profitability Of Large Pharmaceutical Companies Compared With Other Large Public Companies, Fred D. Ledley, Sarah Shonka Mccoy, Gregory Vaughan, Ekaterina Galkina Cleary
Natural & Applied Sciences Faculty Publications
Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry’s ability to innovate and provide essential medicines.
The Impact Of Bone Marrow Transplantion On Patients With Psychiatric Diagnoses: Medication Adherence Assessment, Brittany Galop
The Impact Of Bone Marrow Transplantion On Patients With Psychiatric Diagnoses: Medication Adherence Assessment, Brittany Galop
Theses and Dissertations--Pharmacy
Objectives: We investigated whether there is a measurable difference in medication utilization for psychiatric conditions before and after bone marrow transplantation (BMT). Previous studies have identified a potential association between psychiatric conditions and immune function. We hypothesized that medication utilization for psychiatric diagnoses would be impacted by BMT.
Methods: This study was a retrospective, quasi-experimental cohort design. De-identified data was compiled from the Truven database for patients ranging from January 2009 through December 2016. Two measurements of medication utilization, proportion of days covered (PDC) and medication possession ratio (MPR) were calculated for each included Medispan-defined class of medications before analyzing …
340b Program Utilization In Rural Us Clinics, William Finley, Heather M. Kruel
340b Program Utilization In Rural Us Clinics, William Finley, Heather M. Kruel
Theses, Dissertations and Capstones
Introduction: The 340B program was an effective strategy in reaching more potential patients, providing more comprehensive services, and limiting the gap between affordability and healthcare. The uninsured and underprivileged often are unable to receive medications at the high market price due to the financial situation they face and inflation. The 340B program seeked to mend this issue to help the public and healthcare organizations. The main purpose of this research was to search and evaluate if the 340B program lived up to its purpose of decreasing the cost of medications in rural based clinics.
Methodology: The research strategy developed …
Predictors Of Cardiovascular And Gastrointestinal Disorders, Inappropriate Nonsteroidal Anti-Inflammatory Drug Use, And Alzheimer’S Disease And Related Dementia In Older Adults With Osteoarthritis, Jayeshkumar Patel
Graduate Theses, Dissertations, and Problem Reports (ETD)
Osteoarthritis (OA) is a degenerative arthritis affecting over 30 million Americans most of whom are over 65 years or older. Its clinical management is complicated by several disease- and treatment-specific factors. These include the co-occurrence of cardiovascular and gastrointestinal disorders (CV-GID), the inappropriate use of non-steroidal anti-inflammatory drugs (NSAID) to manage pain, and the risk of certain age-related chronic conditions like Alzheimer’s disease and related dementia (ADRD). Moreover, older adults with OA are at a higher risk of CV-GID, inappropriate NSAID use, and ADRD. Additionally, these factors can also affect one another in both a positive and a negative way. …
Multimorbidity, Immune Checkpoint Inhibitor Use, And Healthcare Expenditures Among Older Patients With Late-Stage Melanoma, Pragya Rai
Graduate Theses, Dissertations, and Problem Reports (ETD)
With decades of unchanged cancer care with no added survival benefit, immune checkpoint inhibitors (ICI) changed the treatment landscape of late-stage melanoma in 2011. A key factor in determining the use of ICIs is the presence of pre-existing chronic conditions, which can influence the outcome. However, the prevalence of multimorbidity (defined as presence of two or more chronic conditions) among older patients with late-stage melanoma remains unknown. It also remains unknown if the presence of multimorbidity factors into the use of ICIs. Hospital-related factors associated with ICI use have been studied. Yet, patient-level factors, such as age, sex, marital status, …
Development And Validation Of Predictive Risk And Multiple Criteria Decision Analysis Models To Evaluate Cardiovascular Outcomes Among Cancer Patients, Purva N. Parab
Theses and Dissertations
Objective: The objectives of our study were to characterize the study population with cancer and cardiovascular diseases (CVD) both as compared to those without and to build a predictive model using machine learning (ML) algorithms that can predict the risk of CVD in cancer patients. In addition, our objective was also to evaluate characteristics associated with cardiotoxic adverse events of breast cancer therapies and develop a multiple criteria decision analysis (MCDA) model to conduct benefit-risk assessment of breast cancer therapy regimens. Methods: We used Medical Expenditure Panel Survey (MEPS) and FDA Adverse Events Reporting System (FAERS) 2005-2015 files along with …
Implementation Of A Pharmacist-Driven Prescription Delivery And Home Visitation Service In A Rural Community, Clayton L. Miller, Katie Westgerdes, Michael Rush, Karen L. Kier, Megan Stephan
Implementation Of A Pharmacist-Driven Prescription Delivery And Home Visitation Service In A Rural Community, Clayton L. Miller, Katie Westgerdes, Michael Rush, Karen L. Kier, Megan Stephan
Pharmacy Faculty Scholarship
No abstract provided.
Preserving Ancient Cultures Through Medicinal Narratives, Mckenzie Jewel Moss
Preserving Ancient Cultures Through Medicinal Narratives, Mckenzie Jewel Moss
Honors Projects
“Preserving Ancient Cultures through Medicinal Narratives” is a comprehensive project that takes an interdisciplinary approach to understanding the effects that culture has on health. The project as a whole includes the initial work and readings I performed to better understand differences in healing between the cultures found throughout South America, where Inca culture is still prevalent, and that of the Unites States, as well as an independent documentary. The documentary contains my own personal commentary complemented by video clips of interviews I performed with individuals living in South America.
Discussing The Future Of Drug Development And The Pharmaceutical Marketplace, Brittiany Feher, Brady Giles, Gina Jones, Karen Kier, Chet Kaczor
Discussing The Future Of Drug Development And The Pharmaceutical Marketplace, Brittiany Feher, Brady Giles, Gina Jones, Karen Kier, Chet Kaczor
Pharmacy and Wellness Review
No abstract provided.
Accountable Care Organizations: What Pharmacists Should Know, Kaitlin M. Horton, Rachel J. Pucel, Alison L. Streinbrunner, Lindsay A. Fleegle, Donald L. Sullivan
Accountable Care Organizations: What Pharmacists Should Know, Kaitlin M. Horton, Rachel J. Pucel, Alison L. Streinbrunner, Lindsay A. Fleegle, Donald L. Sullivan
Pharmacy and Wellness Review
No abstract provided.
Improving Healthcare Costs And Patient Outcomes Across Healthcare Professions, Hannah Lamb, Jourdan Ujlaki, Paige Torbet, Isabel Cwikla, Rebecca Worden, Michael Rush
Improving Healthcare Costs And Patient Outcomes Across Healthcare Professions, Hannah Lamb, Jourdan Ujlaki, Paige Torbet, Isabel Cwikla, Rebecca Worden, Michael Rush
Pharmacy and Wellness Review
Healthcare professionals must be aware of the importance of preventive medicine and the responsibility they have in contributing to it. There are three levels of preventive medicine that a healthcare professional can provide based on the patient population that is receiving care and the goals of the particular service. Preventive medicine has the ability to improve both overall healthcare costs and have a positive impact on a patient's quality of life. All healthcare professionals have the potential to fulfill a role in each level of preventive medicine, and should understand the role of each member of the healthcare team, to …
Treatment Patterns And Economic Burden Of Sickle-Cell Disease Patients Prescribed Hydroxyurea: A Retrospective Claims-Based Study, Nirmish Shah, Menaka Bhor, Lin Xie, Rashid Halloway, Steve Arcona, Jincy Paulose, Huseyin Yuce
Treatment Patterns And Economic Burden Of Sickle-Cell Disease Patients Prescribed Hydroxyurea: A Retrospective Claims-Based Study, Nirmish Shah, Menaka Bhor, Lin Xie, Rashid Halloway, Steve Arcona, Jincy Paulose, Huseyin Yuce
Publications and Research
Background: This study aimed to evaluate sickle-cell disease (SCD) treatment patterns and economic burden among patients prescribed hydroxyurea (HU) in the US, through claims data.
Methods: SCD patients with pharmacy claims for HU were selected from the Medicaid Analytic Extracts (MAX) from January 1, 2009 - December 31, 2013. The first HU prescription during the identification period was defined as the index date and patients were required to have had continuous medical and pharmacy benefits for ≥6 months baseline and 12 months follow-up periods. Patient demographics, clinical characteristics, treatment patterns, health care utilization, and costs were examined, and variables were …
Makena®: A Drug For Reducing The Risk Of Preterm Labor, Amanda Lovell, Kasie Bellman, Kelsey Fink, Jessica Beck, Michelle Musser
Makena®: A Drug For Reducing The Risk Of Preterm Labor, Amanda Lovell, Kasie Bellman, Kelsey Fink, Jessica Beck, Michelle Musser
Pharmacy and Wellness Review
Makena®, hydroxyprogesterone caproate, is an intramuscular injection that is U.S. Food and Drug Administration (FDA) approved to reduce the risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of spontaneous preterm birth, who are not currently carrying multiple children. One in nine babies born in the United States each year is born prematurely, or before 37 weeks gestation, and mothers who have previously delivered a premature baby are 2.5 times more likely to deliver another baby prematurely. Makena® is administered by a health care professional as a single intramuscular injection to the hip and …
Joint Annual Wellness Visit Scheduling, Rob Chamberlin, Jennifer Bliss, Andrea Lai, Paula Dougherty, Deb Swett, Logan Merrithew, Pam Stevens, Scott Williams
Joint Annual Wellness Visit Scheduling, Rob Chamberlin, Jennifer Bliss, Andrea Lai, Paula Dougherty, Deb Swett, Logan Merrithew, Pam Stevens, Scott Williams
MaineHealth Maine Medical Center
Problem/Impact Statement: The pharmacists in Scarborough & Westbrook Primary Care conduct Medicare Annual Wellness Visits (AWVs) with a physician. The pharmacist and physician see the patient individually. The practices achieved and sustained FY18 Joint AWV volume goals through a new process to reschedule physician-only AWVs to Joints AWVs with a pharmacist. This leads to reschedule rework and reduced time practice staff have for patient care.
Marketing Channel Effectiveness Of New Medications/Medical Technology, Hadley Mccormick
Marketing Channel Effectiveness Of New Medications/Medical Technology, Hadley Mccormick
Celebration of Learning
This research project will study what marketing platforms/channels are most effective in the dissemination of new medical product news. Many people like myself have an illness/disease that requires daily medication, or require the daily use of a medical device. Due to the increasing influence of Direct to Consumer advertising of pharmaceuticals and the constant development of new medications and devices, patients may now more often go to the doctor with perceptions of what they should do to manage their illness/disease. This study aims to look at how the developers of these medications/medical devices promote their products currently and how certain …
Ethnic And Demographic Differences In Colectomy Rates And Timing For Ulcerative Colitis: 2007-2014, Daniel Bodek, Alana Persaud, Brian Blair, Ahlawat Sushil
Ethnic And Demographic Differences In Colectomy Rates And Timing For Ulcerative Colitis: 2007-2014, Daniel Bodek, Alana Persaud, Brian Blair, Ahlawat Sushil
Rowan-Virtua Research Day
Ulcerative Colitis (UC) is a chronic inflammatory disease of the bowel, with one third of patients requiring a colectomy for fulminant disease and tissue dysplasia. In 2007, infliximab was approved for induction and maintenance of remission in UC, with some evidence to suggest a potential reduction in colectomies. The aim of this study is to examine relative colectomy rates for UC among different ethnicities from 2007 to 2014 in order to evaluate for development of new trends or disparities.
Discrepancies in colectomy rates and timing are seen in our models which mirror closely findings in a prior study from 1999-2003 …
The Landscape Of Cellular And Gene Therapy Products: Cost, Approvals, And Discontinuations, Vaishali Shukla, Enrique Seoane-Vazquez, Souhiela Fawaz, Lawrence M. Brown, Rosa Rodriguez-Monguio
The Landscape Of Cellular And Gene Therapy Products: Cost, Approvals, And Discontinuations, Vaishali Shukla, Enrique Seoane-Vazquez, Souhiela Fawaz, Lawrence M. Brown, Rosa Rodriguez-Monguio
Pharmacy Faculty Articles and Research
Background The past 10 years witnessed a significant increase in the approval of cellular and gene therapy products worldwide. The US Food and Drug Administration (FDA) approved 3 gene therapy products within the last 4 months of 2017. The objective of this study was to examine the approval characteristics, discontinuations and cost of all cellular and gene therapy products approved worldwide. Data and Methods We conducted an electronic search of approved cell and gene therapy products from the databases of the main drug regulatory agencies including the US Food and Drug Administration, the European Medicines Agency (EMA), the Korea Ministry …
Predictors And Health Outcomes Of Treatment-Resistant Depression Among Adults With Chronic Non-Cancer Pain Conditions And Major Depressive Disorder, Drishti Shah
Graduate Theses, Dissertations, and Problem Reports (ETD)
Understanding major depressive disorder (MDD) as a comorbidity in patients with chronic non-cancer pain conditions (CNPC) is of importance because of the high prevalence and well documented bi-directional relationship between MDD and pain. Furthermore, presence of CNPC among adults with MDD often reduces benefits of antidepressant therapy, thereby increasing the possibility of treatment resistance. Treatment-resistant depression (TRD) commonly defined as insufficient response to multiple antidepressant trials, often worsens depression and pain symptoms and can amplify the clinical and economic burden among adults with CNPC and MDD. Additionally, long-term opioid therapy (LTOT) may be prescribed at a higher rate to adults …
The Orphan Drug Act At 35: Observations And An Outlook For The Twenty-First Century, Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite
The Orphan Drug Act At 35: Observations And An Outlook For The Twenty-First Century, Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite
Articles
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new orphan drugs appears to be greater today than it was in 1983. All else equal, this should reduce the threshold for research and development (R&D) investment in an economically viable product. Further, the small size of patient populations for orphan drugs, together with the increasing prevalence of biologics among orphan drugs, have created a set …
Cost Effectiveness Analysis Of Enzalutamide, Abiraterone Plus Prednisone And Cabazitaxel Plus Predinsone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi
Pharmaceutical Sciences ETDs
Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. Of those diagnosed with prostate cancer, about 10-20 % will develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and 70 % of those cases will metastasize to mCRPC. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020; making prostate cancer the fifth most costly cancer.
Objective: To conduct a cost-effective analysis …
Multiple Sclerosis Drugs Have Been Getting A Lot More Expensive, Ben Jay
Multiple Sclerosis Drugs Have Been Getting A Lot More Expensive, Ben Jay
Capstones
Multiple Sclerosis is a very expensive disease. According to a 2016 study in the American Journal of Managed Care, treating it can cost patients anywhere from $30,000 to $100,000 per year, which can meet or even exceed the average US household median income, depending on how severe your case is. For a disease that has no known cure, and requires frequent medical attention to manage symptoms that can completely debilitate a person if left untreated, that can mean spending $4.1 million over the course of a lifetime, according to the same study. However, in the last 20 years, that …
Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany
Save The Pharmacy Piggy Bank: Managing Mega High-Cost Drugs, Richard K. Ogden Jr., Jerame Hill, Sam Abdelghany
Pharmacy Presentations
No abstract provided.